Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Bibliographic Details
Main Authors:	DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Format:	Conference item
Language:	English
Published:	American Society of Hematology 2021

Similar Items